CYP19A1 and ductal breast carcinoma in situ: Endocrine therapy with Tamoxifen or an aromatase inhibitor may be considered for ER-positive DCIS treated with mastectomy with sentinel lymph node biopsy or breast-conserving therapy (BCT); the benefit of endocrine therapy for ER-negative DCIS is unknown.